A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

NCT04238819 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

47

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed Solid Tumor
Refractory Solid Tumor

Interventions

DRUG: Abemaciclib
DRUG: Irinotecan
DRUG: Temozolomide
DRUG: Dinutuximab
DRUG: GM-CSF

Sponsor

Eli Lilly and Company